Improve your mental health and well-being through psychedelic therapy

A New Frontier in Mental Health with Psychedelic Therapy

Experience the groundbreaking benefits of psychedelic therapy, a scientifically-backed approach revolutionizing how we understand and treat mental health disorders, offering hope and healing to countless individuals.

Envision Mind Care & Research Institute is one of the largest and most advanced psychedelic treatment centres in Western Canada. Located in Edmonton, Alberta, our state-of-the-art facility spans over 4 floors and 30,000 square feet, providing a comprehensive and holistic approach to mental health and wellness. Our team of medical health care professionals and trained staff members are dedicated to providing cutting-edge therapies, including Psilocybin therapy, Ketamine therapy, and MDMA therapy, in a supportive and nurturing environment.

Our unique combination of a medical institution and wellness retreat allows us to offer additional support services, such as psychiatry, psychology, dieticians, weight loss, and addiction treatment. At Envision Mind Care & Research Institute, we attract clients, doctors, and medical professionals from across Canada and beyond who are seeking the transformative benefits of psychedelic therapies.

We are fully Accredited by the College of Physicians and Surgeons of Alberta for Psychedelic-Assisted Psychotherapy.

Our clinic is one of the first Alberta clinics to achieve an accredited status from the CPSA of Alberta for Psychedelic-Assisted Psychotherapy (PAP). CPSA Accreditation is vital to achieve a medical care and culture standard within Alberta’s medical facilities. At Envision Mind Care, clients can experience Psychedelic-Assisted Psychotherapy knowing the clinic’s facility, procedures, and staff meet a high-quality standard.

Our Psychedelic Treatments

Psilocybin Therapy
(Coming Jan 2024*)

Psilocybin therapy is a groundbreaking treatment option for individuals suffering from mental health conditions such as depression, anxiety, and PTSD. Psilocybin, a naturally occurring compound found in certain species of mushrooms, has been shown to promote lasting, positive changes in mental well-being. Our experienced team administers psilocybin in a controlled and supportive environment, ensuring our clients' safe and transformative experience.

Learn more about Psilocybin therapy

*Clients will be placed on a waitlist due to the high demand for this service.

Ketamine Therapy
(Now available)

Ketamine therapy is a promising treatment for individuals with treatment-resistant depression, anxiety, and PTSD. As a dissociative anesthetic, ketamine can provide rapid relief from symptoms by creating new neural connections in the brain, promoting improved mental health. At Envision Mind Care & Research Institute, our skilled professionals administer ketamine in a controlled setting, providing clients with a safe and effective therapeutic experience.

Learn more about Ketamine therapy

MDMA Therapy
(Awaiting approval)

MDMA therapy is innovative in treating mental health disorders such as PTSD, anxiety, and depression. MDMA is a synthetic compound that facilitates deep emotional processing and healing. At Envision Mind Care & Research Institute, our experienced team guides clients through MDMA-assisted therapy sessions in a safe, supportive, and medically-supervised environment.

Key Benefits of Psychedelic Therapy

Significant Reduction in Symptoms

In a clinical trial of psilocybin-assisted therapy for depression, over 70% of participants experienced a clinically significant reduction in symptoms after just one week of treatment.

Fast removal of PTSD majority of participants

A study of MDMA-assisted therapy for PTSD found that after just two sessions, 54% of participants no longer met the criteria for PTSD diagnosis.

Long-term improvements for anxiety and depression.

A survey of cancer patients found that psilocybin-assisted therapy significantly reduced anxiety and depression, with up to 80% of participants reporting long-term improvements in mood and well-being.

Long-term results for smoking cessation

In a follow-up study of participants in a psilocybin-assisted therapy trial for smoking cessation, 80% of participants were still abstinent from smoking six months after treatment, compared to just 35% of participants in a control group.

A place to heal

We welcome out-of-province clients

Clients visit from across Canada and throughout the globe to get the complete care provided by Envision Mind Care & Research Institute.

A Brief History of Psychedelics

Psychedelics, or mind-altering substances, have been used by indigenous cultures for thousands of years for spiritual and healing purposes. However, in the 1960s, due to their association with counterculture and the rise of recreational drug use, psychedelics were deemed illegal and their potential for medicinal use was largely ignored. In recent years, however, modern society and medicine have begun to rediscover the safe use of psychedelics for healing and therapy.

Many countries have been actively looking into the science-based evidence and psychedelics' efficacy in treating major depressive disorders, PTSD, and others. Psilocybin, the active ingredient in "magic mushrooms," has shown promising results in reducing symptoms of depression and anxiety. Ketamine, a dissociative anesthetic, has also shown potential for treating depression and suicidal ideation. MDMA, commonly known as ecstasy, has been used in clinical trials to treat PTSD with promising results.

While more research is needed, the potential of psychedelics as a safe and effective treatment option for mental health disorders is becoming increasingly clear. Many people have reported finding joy and relief from their conditions through the use of psychedelics in a therapeutic setting. As society continues to explore the potential of these substances, we may see a shift towards more holistic and integrative approaches to mental health treatment

Key benefits of psychedelics as used in therapeutic settings

  • Treatment of mental health disorders: Psychedelics such as psilocybin, ketamine, and MDMA have shown promise in treating a range of mental health disorders, including depression, anxiety, PTSD, and addiction.

  • Enhanced emotional well-being: Psychedelics have been reported to increase emotional openness, enhance empathy and compassion, and improve overall emotional well-being.

  • Increased mindfulness: Psychedelics have been shown to increase mindfulness, which can lead to improved self-awareness, emotional regulation, and overall psychological well-being.

  • Spiritual experiences: Psychedelics have been used for centuries to induce spiritual experiences, and some research suggests that they may have therapeutic value for individuals seeking spiritual or mystical experiences.

  • Improved creativity: Psychedelics have been reported to enhance creativity and problem-solving abilities, which may have implications for individuals in creative professions or those seeking personal growth and development

  • Micro-dosing: Micro-dosing involves taking sub-hallucinogenic doses of psychedelics on a regular basis, typically over weeks or months. Some studies suggest that micro-dosing psilocybin may improve mood, creativity, and cognitive function, although more research is needed to understand its effects fully.

    One major study on micro-dosing psilocybin was conducted in 2018 by researchers at Imperial College London. The study found that participants who micro-dosed psilocybin experienced improved mood, creativity, and focus and reduced symptoms of anxiety and depression. However, the study was small, and more research is needed to confirm these findings.

FAQ and Additional Questions

  • Psychedelic treatments can be classified into two main categories: macro-dose and micro-dose. Macro-dose treatments involve a single administration session followed by an integration phase, while micro-dose treatments involve taking small doses over an extended period of time. The duration of treatment can vary depending on the specific substance, dosage, and treatment protocol being used. The use of psychedelic substances for therapeutic purposes is still a new and evolving field, and should only be undertaken in the context of a clinical trial with the guidance of a qualified treatment team.

  • The recovery time after a clinical psychedelic treatment varies depending on the type of treatment and the individual's response. Macro-dose treatments involve a single high dose and are associated with a longer recovery time than micro-dose treatments, which involve small doses over time. Macro-dosing typically involves an acute phase followed by an integration phase lasting several weeks or months, while micro-dosing may have milder and shorter-lived effects, but still require a period of reflection and integration.

  • It is necessary to have a physician (general or specialist) refer you as your own general physician and psychiatrist would continue to oversee your physical and mental health during the course of rTMS treatment.

  • The use of psychedelics for treating major depressive disorder has been the subject of numerous clinical studies in recent years, with many showing promising results. For example, a study published in JAMA Psychiatry in 2021 found that a single dose of psilocybin, the active ingredient in "magic mushrooms," produced rapid and sustained improvements in depressive symptoms in individuals with major depressive disorder (Davis et al., 2021). While the exact likelihood of achieving full or temporary relief of symptoms with psychedelic treatments can vary, these findings highlight the potential of psychedelic therapies as a new and promising approach to treating depression.

    Reference:

    Davis, A. K., Barrett, F. S., May, D. G., et al. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481-489. doi: 10.1001/jamapsychiatry.2020.3285.

  • The concurrent use of other psychiatric medications alongside the clinical use of psychedelics is a complex issue that requires careful consideration by a qualified treatment team. While there is limited research on the interactions between psychedelics and other psychiatric medications, it is generally recommended that individuals discontinue the use of such medications prior to a psychedelic treatment. This is because many psychiatric medications, such as selective serotonin reuptake inhibitors (SSRIs), can interfere with the effects of psychedelics and potentially increase the risk of adverse reactions. However, the decision to discontinue psychiatric medications should be made on a case-by-case basis, and individuals should only do so under the guidance and supervision of their healthcare provider. Ultimately, the use of psychedelic therapies should only be undertaken in the context of a carefully designed and supervised clinical trial, with the guidance of a qualified treatment team.

  • While clinical psychedelic therapy has shown promising results in treating various mental health conditions, it is not appropriate for everyone. Individuals with a history of severe mental illness, such as psychosis or schizophrenia, may be at increased risk of adverse reactions to psychedelic treatments and should not undergo this form of therapy. Additionally, individuals with a history of substance abuse or addiction may also be at increased risk of adverse reactions and should be carefully evaluated before undergoing psychedelic treatment.

    Other factors that may disqualify someone from receiving psychedelic therapy include pregnancy or a history of certain medical conditions. It is important to work with a qualified healthcare provider to determine if psychedelic therapy is appropriate and safe for an individual's specific needs and circumstances.

  • Clinical psychedelics have shown potential in treating a range of mental health disorders. Here are some of the disorders that have been studied in clinical trials:

    Major depressive disorder

    Anxiety disorders, including generalized anxiety disorder and social anxiety disorder

    Post-traumatic stress disorder (PTSD)

    Obsessive-compulsive disorder (OCD)

    Substance use disorders, including alcohol and tobacco addiction

    Eating disorders, such as anorexia nervosa and bulimia nervosa

    Cluster headaches

    End-of-life distress in individuals with life-limiting illnesses

    It's important to note that while psychedelics may hold promise for treating these disorders, clinical trials are ongoing and further research is needed to fully understand their potential benefits and risks. Additionally, it's crucial to undergo psychedelic therapy under the supervision of a qualified healthcare provider in the context of a carefully designed and supervised clinical trial.